Cover Image
市場調查報告書

兔熱病:開發中產品分析

Tularaemia - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 293888
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
兔熱病:開發中產品分析 Tularaemia - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 80 Pages
簡介

兔熱病(tularaemia)是由一種被稱為土拉桿菌(Francisella tularensis)的細菌所引起的感染病。主要是因被節肢動物(特別是扁虱和蚊子)虰咬感染。 藉由皮膚、結膜囊、口腔咽喉黏膜與感染的動物及動物性物質直接接獨、或攝取到被污染的食品及水、吸入被污染的灰塵粉霧而感染。主要症狀有皮膚潰瘍、淋巴腺腫大和疼痛、發燒、發冷等。治療方法包含了抗生素和健康生活習慣等。

本報告提供兔熱病治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

兔熱病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Aradigm Corporation
  • Arno Therapeutics, Inc.
  • DynPort Vaccine Company LLC
  • Emergent BioSolutions Inc.
  • EpiVax, Inc.
  • Grifols, S.A.
  • Merck & Co., Inc.
  • Tetraphase Pharmaceuticals Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 按給藥法
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8128IDB

Summary

Global Markets Direct's, 'Tularaemia - Pipeline Review, H1 2016', provides an overview of the Tularaemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tularaemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Tularaemia
  • The report reviews pipeline therapeutics for Tularaemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Tularaemia therapeutics and enlists all their major and minor projects
  • The report assesses Tularaemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Tularaemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Tularaemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tularaemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tularaemia Overview
  • Therapeutics Development
    • Pipeline Products for Tularaemia - Overview
    • Pipeline Products for Tularaemia - Comparative Analysis
  • Tularaemia - Therapeutics under Development by Companies
  • Tularaemia - Therapeutics under Investigation by Universities/Institutes
  • Tularaemia - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Tularaemia - Products under Development by Companies
  • Tularaemia - Products under Investigation by Universities/Institutes
  • Tularaemia - Companies Involved in Therapeutics Development
    • Aradigm Corporation
    • Arno Therapeutics, Inc.
    • DynPort Vaccine Company LLC
    • Emergent BioSolutions Inc.
    • EpiVax, Inc.
    • Grifols, S.A.
    • Merck & Co., Inc.
    • Tetraphase Pharmaceuticals Inc.
  • Tularaemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AR-12 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARD-3100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARD-3150 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ciprofloxacin hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EV-035 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SRI-011225 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-271 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tularaemia [strain A] vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tularaemia [strain B] vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tularaemia vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tularemia vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Tularaemia - Recent Pipeline Updates
  • Tularaemia - Dormant Projects
  • Tularaemia - Discontinued Products
  • Tularaemia - Product Development Milestones
    • Featured News & Press Releases
      • Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015
      • May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12
      • Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Tularaemia, H1 2016
  • Number of Products under Development for Tularaemia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Tularaemia - Pipeline by Aradigm Corporation, H1 2016
  • Tularaemia - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Tularaemia - Pipeline by DynPort Vaccine Company LLC, H1 2016
  • Tularaemia - Pipeline by Emergent BioSolutions Inc., H1 2016
  • Tularaemia - Pipeline by EpiVax, Inc., H1 2016
  • Tularaemia - Pipeline by Grifols, S.A., H1 2016
  • Tularaemia - Pipeline by Merck & Co., Inc., H1 2016
  • Tularaemia - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Tularaemia Therapeutics - Recent Pipeline Updates, H1 2016
  • Tularaemia - Dormant Projects, H1 2016
  • Tularaemia - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Tularaemia, H1 2016
  • Number of Products under Development for Tularaemia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top